Request Demo
Last update 25 Jul 2025
Sampeginterferon beta-1a(Biocad Medical)
Last update 25 Jul 2025
Overview
Basic Info
Drug Type Interferons |
Synonyms TENEXIA, BCD 054, BCD-054 |
Target |
Action agonists, modulators |
Mechanism IFNAR agonists(Interferon alpha/beta receptor agonists), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 12364
Source: *****
Related
2
Clinical Trials associated with Sampeginterferon beta-1a(Biocad Medical)NCT02744222
An International Multicenter Double-blind Placebo-controlled Randomized Study to Compare the Efficacy, Safety and Tolerability of BCD-054 (JSC BIOCAD, Russia), 180 μg and 240 μg, Versus Avonex® (Biogen Idec Ltd., UK) in Patients With Relapsing-remitting Multiple Sclerosis
NCT02359877
Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers
100 Clinical Results associated with Sampeginterferon beta-1a(Biocad Medical)
Login to view more data
100 Translational Medicine associated with Sampeginterferon beta-1a(Biocad Medical)
Login to view more data
100 Patents (Medical) associated with Sampeginterferon beta-1a(Biocad Medical)
Login to view more data
1
Literatures (Medical) associated with Sampeginterferon beta-1a(Biocad Medical)01 Jan 2019Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis
Article
Author: Bakhtiyarova, K Z ; Ivanov, R A ; Chernovskaya, T V ; Linkova, Yu N ; Malkova, N A ; Zaslavsky, L G ; Zinkina-Orikhan, A V ; Boyko, A N ; Dudin, V A ; Fedulov, A S ; Parshina, Ye V
100 Deals associated with Sampeginterferon beta-1a(Biocad Medical)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Russia | 10 Aug 2017 | |
| Multiple Sclerosis | Phase 3 | - | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free